The first Phase l study showed that TB-403 was safe and well tolerated,
with a pharmacokinetic profile which would allow it to be developed as
a treatment for cancer. TB-403 has moved into a Phase Ib trial. This
study will look at the tolerability, pharmacokinetics and
pharmacodynamics of TB-403 in patients with advanced cancer.
- Microplasmin: Positive results announced in Phase II
clinical trials for ophthalmic indications. Positive results were
reported in ThromboGenics' Phase IIb MIVI III trial in patients with a
number of back of the eye conditions. The trial showed that the most
effective dose of microplasmin studied (125 micro g) was able to
resolve the underlying disease in approximately 30% of patients and
consequently achieved the avoidance of surgical intervention in those
Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.
ThromboGenics has continued to work to broaden the Company's
shareholder base. In July, ThromboGenics announced the acquisition of an 8%
stake in the Company by a group of private investors based in Belgium in a
transaction coordinated by Petercam. Their stake was purchased from Biggar
Limited, a charitable foundation that is ThromboGenics' largest
shareholder. Biggar intends to remain an important shareholder in
ThromboGenics for the long term.
- In the first six months of 2008, revenue amounted to EUR30.3
million. This much higher level of revenue is due to Roche's upfront
payment following the signed co-development deal on TB-403. Operating
expenses were EUR13.0 million in the first half, the majority of which
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved